ProMIS Neurosciences, Inc. (PMN)
PMN Stock Price Chart
Explore ProMIS Neurosciences, Inc. interactive price chart. Choose custom timeframes to analyze PMN price movements and trends.
PMN Company Profile
Discover essential business fundamentals and corporate details for ProMIS Neurosciences, Inc. (PMN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jan 2007
Employees
7.00
CEO
Neil K. Warma
Description
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
PMN Financial Timeline
Browse a chronological timeline of ProMIS Neurosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.15.
Earnings released on 13 Aug 2025
EPS came in at -$0.29 falling short of the estimated -$0.22 by -31.82%.
Earnings released on 12 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.12 by -75.00%.
Earnings released on 31 Mar 2025
EPS came in at -$0.02 surpassing the estimated -$0.14 by +85.71%.
Earnings released on 14 Nov 2024
EPS came in at -$0.14 falling short of the estimated -$0.07 by -100.00%.
Earnings released on 8 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.14 by +7.14%.
Earnings released on 14 May 2024
EPS came in at -$0.19 surpassing the estimated -$0.20 by +5.00%.
Earnings released on 1 Apr 2024
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%, while revenue for the quarter reached $4.72K .
Earnings released on 14 Nov 2023
EPS came in at -$0.19 surpassing the estimated -$0.33 by +42.42%.
Earnings released on 14 Aug 2023
EPS came in at -$0.27 .
Earnings released on 15 May 2023
EPS came in at -$0.58 .
Earnings released on 8 Mar 2023
EPS came in at -$0.90 , while revenue for the quarter reached -$3.11K .
Earnings released on 14 Nov 2022
EPS came in at -$0.85 .
Earnings released on 12 Aug 2022
EPS came in at -$0.38 .
Stock split effective on 28 Jun 2022
Shares were split 1 : 60 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 May 2022
EPS came in at -$0.60 , while revenue for the quarter reached $2.67K .
Earnings released on 31 Dec 2021
EPS came in at -$0.30 , while revenue for the quarter reached $3.25K .
Earnings released on 12 Nov 2021
EPS came in at -$0.16 , while revenue for the quarter reached $3.15K .
Earnings released on 12 Aug 2021
EPS came in at -$0.04 .
Earnings released on 14 May 2021
EPS came in at -$0.98 falling short of the estimated -$0.45 by -114.93%.
Earnings released on 31 Dec 2020
EPS came in at -$0.12 , while revenue for the quarter reached $174.31 .
Earnings released on 11 Nov 2020
EPS came in at -$0.60 matching the estimated -$0.60.
PMN Stock Performance
Access detailed PMN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.